CClinicalTrials.gg
CompletedNCT02977598Updated Nov 30, 2016

Relations Between Atherogenic Index of Plasma-Glucose Metabolism

An observational study in Diabetes Mellitus Risk, sponsored by Erzincan University. Completed at 2 sites in Turkey. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-11-30.

Sponsored by Erzincan University · Observational

Study type
Observational
Enrollment
448
Ages
18 Years to 80 Years
Sex
All
01

Study summary

In this study, the investigators aimed to find out whether there is any association between the atherogenic index of plasma with the glucose metabolism.In this respect, apart from the well-known diabetic risk factors, the investigators purposed to reveal new ones.

Read the detailed description

Atherogenic index of plasma (AIP) is a relatively new index and a predictor of cardiovascular risk. AIP has been shown to be associated with impaired glucose metabolism. This study aimed to evaluate the relationship between AIP and parameters of glucose metabolism.

Methods: This observational study involved 448 healthy individuals who were at risk for diabetes. They were sent to hospital for diabetes check. According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association (ADA). The association between the diabetes group, AIP and parameters of glucose metabolism was analyzed.

The accuracy of registry data compatible with medical records. Statistical analyses were carried out using the Statistical Package for Social Sciences, Windows version 15.0 (SPSS, Chicago, Illinois, USA). Descriptive statistics for each variable were determined. Normality of the data distribution was assessed with the Kolmogorov-Smirnov test. For continuous variables, non-parametric statistics (Mann-Whitney or Kruskal-Wallis), and parametric statistics (t-test, ANOVA analysis) were used as appropriate. Statistically significant differences between the groups were determined by the chi-square test for categorical variables. Associations between the variables were explored using the Pearson correlation and Spearman's rho (for data that was not normally distributed). Linear regression analysis with backward elimination was also performed to define variables associated with AIP.

02

Conditions studied

  • Diabetes Mellitus Risk

Browse trials for

03

In context

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's enrollment of 448 is above the median of 233 across 2,220 observational studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Erzincan University is the lead sponsor of 42 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

448 healthy individuals who were at risk for diabetes. According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.

Inclusion criteria

  • All the participants were previously healthy, aged between 18 and 80 years, and were at risk for diabetes according to new criteria provided by the American Diabetes Association.

Exclusion criteria

Exclusion Criteria:

  • Individuals with a history of chronic medical diseases and those who reported current use of any medication were excluded from the study
05

Study design

Enrollment
448 participants (actual)
Patient registry
No

Groups and cohorts

  • non-diabetic

    According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.

  • prediabetic

    According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.

  • diabetic

    According to the 75 g oral glucose tolerance test participants were categorized into the three groups; non-diabetic, prediabetic, and diabetic based on the criteria of the American Diabetes Association.

06

What researchers measure

Primary outcomes

  1. Atherogenic index of plasma (AIP) values compared with glucose metabolism parameters like HbA1c, Fasting Plasma Glucose and 2-hour plasma glucose levels.

    Time frame: 6 months

07

Study locations

2 sites
  • Erzincan Mengucekgazi Research and Training Hospital
    Erzincan, 00024, Turkey
  • Erzincan Mengücekgazi Training and Research Hospital
    Erzincan, 00024, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02977598
Lead sponsor
Erzincan University
Responsible party
HILAL ALPCAN (Internal medicine, medical doctor, Erzincan University) — Principal investigator
First posted
Nov 30, 2016
Start date
Feb 2014
Primary completion
Dec 2014
Completion
Feb 2015
Last update
Nov 30, 2016

Study contacts

EMIN MURAT AKBAS, Assoc. Prof.
principal investigator · ERZINCAN MENGUCEKGAZI TRAINING AND RESEARCH HOSPİTAL DEPARTMENT OF ENDOCRINOLOGY AND METABOLIC DISEASES

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion